Patents
Literature
Patsnap Eureka AI that helps you search prior art, draft patents, and assess FTO risks, powered by patent and scientific literature data.

2 results about "Transmissible gastroenteritis virus" patented technology

Transmissible gastroenteritis coronavirus (TGEV) is a virus belonging to the family Coronaviridae, genus Alphacoronavirus, species Alphacoronavirus 1. TGEV are enveloped viruses with a positive-sense single-stranded RNA genome and a helical symmetry.

A method for detecting multiple porcine diarrhea viruses based on tNGS technology and application thereof

The application discloses a kind of pig multiple diarrhea virus detection method and application based on tNGS technology.The method realizes the accurate detection of pig epidemic diarrhea virus, porcine transmissible gastroenteritis virus and porcine delta coronavirus by tNGS technology.The primer set involved is used to amplify the S1 and M genes of PEDV, the N gene of TGEV and the M gene of PDCoV.The application also provides a kit comprising the primer set and a corresponding tNGS detection method.Clinical sample verification shows that the method is completely consistent with the qPCR detection results, has high sensitivity, strong specificity, can simultaneously identify mixed infection and other advantages, and has high detection throughput, controllable cost, is suitable for accurate diagnosis, epidemiological monitoring and prevention and control of diarrhea virus in pig farm, and has wide application prospect.
Owner:湖北省动物疫病预防控制中心 +1

A s protein mutant of porcine transmissible gastroenteritis virus, subunit vaccine and application thereof

ActiveCN121045346BHigh expressionR&D application prospects are goodVirus peptidesAntiviralsMutantTransmissible gastroenteritis virus
This invention provides a mutant S protein of porcine transmissible gastroenteritis virus (TGEV), a subunit vaccine, and its application; the amino acid sequence of the S protein mutant is shown in SEQ ID NO.3. The S protein mutant of TGEV constructed by this invention is significantly superior to the wild-type SWT protein in both humoral and cellular immunity, and its protein expression level also shows a clear advantage, demonstrating excellent prospects for subunit vaccine development and application. Specifically, in terms of immunity, after the S protein mutant is formulated into a vaccine, this invention can enhance post-immunization antibody levels, TGEV virus neutralizing antibody titers, cellular immune responses, and T lymphocyte proliferation.
Owner:湖南派智生物科技有限公司